Thus, we demonstrate here that SKI-O-703 is a novel selective Syk inhibitor that targets two processes, namely B cell activation and innate inflammatory cell functioning, and consequently inhibits autoAb-mediated manifestations such as SLE and RA. The gene discussed is SYK; the disease is systemic lupus erythematosus.